Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Assets (2016 - 2025)

Abeona Therapeutics has reported Non-Current Assets over the past 15 years, most recently at $14.7 million for Q4 2025.

  • Quarterly results put Non-Current Assets at $14.7 million for Q4 2025, up 81.53% from a year ago — trailing twelve months through Dec 2025 was $54.8 million (up 70.24% YoY), and the annual figure for FY2025 was $14.7 million, up 81.53%.
  • Non-Current Assets for Q4 2025 was $14.7 million at Abeona Therapeutics, down from $15.0 million in the prior quarter.
  • Over the last five years, Non-Current Assets for ABEO hit a ceiling of $52.8 million in Q1 2021 and a floor of $7.9 million in Q3 2024.
  • Median Non-Current Assets over the past 5 years was $12.3 million (2022), compared with a mean of $17.9 million.
  • Biggest five-year swings in Non-Current Assets: tumbled 74.05% in 2022 and later surged 88.59% in 2025.
  • Abeona Therapeutics' Non-Current Assets stood at $23.3 million in 2021, then plummeted by 52.28% to $11.1 million in 2022, then dropped by 25.64% to $8.3 million in 2023, then fell by 2.26% to $8.1 million in 2024, then surged by 81.53% to $14.7 million in 2025.
  • The last three reported values for Non-Current Assets were $14.7 million (Q4 2025), $15.0 million (Q3 2025), and $14.0 million (Q2 2025) per Business Quant data.